Congenital hypogonadotropic hypogonadism (CHH) is classified as Kallmann syndrome (KS) with anosmia/hyposmia or normosmic (n)CHH. Here, we investigated the genetic causes and phenotype-genotype correlations in Japanese patients with CHH.
We enrolled 22 Japanese patients with CHH from 21 families (18 patients with KS and 4 with nCHH) and analyzed 27 genes implicated in CHH by next-generation and Sanger sequencing.
We detected 12 potentially pathogenic mutations in 11 families, with three having a mutation in ANOS1 (X-linked recessive); three and four having a mutation in FGFR1 and CHD7, respectively (autosomal dominant); and one having two TACR3 mutations (autosomal recessive). Among four patients with KS carrying a CHD7 mutation, one had perceptive deafness and two had a cleft lip/palate.
The frequency of CHH genes in the Japanese was compatible with previous reports, except that CHD7 mutations might be more common. Furthermore, partial phenotype-genotype correlations were demonstrated in our cohort.
We wish to thank the individuals and their families for their participation in this study, as well as the clinicians for providing patient samples and information. We thank the Core Laboratory, Nagoya City University Graduate School of Medical Sciences, and also Ms. Masami Banno, Ms. Yumiko Sato and Ms. Naomi Ogasawara (our laboratory staff).
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Boehm U, Bouloux PM, Dattani MT, de Roux N, Dode C, et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 2015;11:547–64.26194704 Search in Google Scholar
2. Albuisson J, Pecheux C, Carel JC, Lacombe D, Leheup B, et al. Kallmann syndrome: 14 novel mutations in KAL1 and FGFR1 (KAL2). Hum Mutat 2005;25:98–9.1560541210.1002/humu.9298 Search in Google Scholar
3. Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, et al. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet 2013;92:725–43.2364338210.1016/j.ajhg.2013.04.008 Search in Google Scholar
4. Pingault V, Bodereau V, Baral V, Marcos S, Watanabe Y, et al. Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am J Hum Genet 2013;92:707–24.2364338110.1016/j.ajhg.2013.03.024 Search in Google Scholar
5. Villanueva C, Jacobson-Dickman E, Xu C, Manouvrier S, Dwyer AA, et al. Congenital hypogonadotropic hypogonadism with split hand/foot malformation: a clinical entity with a high frequency of FGFR1 mutations. Genet Med 2015;17:651–9.2539417210.1038/gim.2014.166 Search in Google Scholar
6. Gianetti E, Tusset C, Noel SD, Au MG, Dwyer AA, et al. TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab 2010;95:2857–67.2033224810.1210/jc.2009-2320 Search in Google Scholar
7. Sidhoum VF, Chan YM, Lippincott MF, Balasubramanian R, Quinton R, et al. Reversal and relapse of hypogonadotropic hypogonadism: resilience and fragility of the reproductive neuroendocrine system. J Clin Endocrinol Metab 2014;99:861–70.10.1210/jc.2013-280924423288 Search in Google Scholar
8. Laitinen EM, Tommiska J, Sane T, Vaaralahti K, Toppari J, et al. Reversible congenital hypogonadotropic hypogonadism in patients with CHD7, FGFR1 or GNRHR mutations. PLoS One 2012;7:e39450.10.1371/journal.pone.003945022724017 Search in Google Scholar
9. Maione L, Brailly-Tabard S, Nevoux J, Bouligand J, Young J. Reversal of congenital hypogonadotropic hypogonadism in a man with Kallmann syndrome due to SOX10 mutation. Clin Endocrinol 2016;85:988–9.10.1111/cen.13231 Search in Google Scholar
10. Richards S, Aziz N, Bale S, Bick D, Das S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.10.1038/gim.2015.3025741868 Search in Google Scholar
11. Bergman JE, de Ronde W, Jongmans MC, Wolffenbuttel BH, Drop SL, et al. The results of CHD7 analysis in clinically well-characterized patients with Kallmann syndrome. J Clin Endocrinol Metab 2012;97:E858–62.10.1210/jc.2011-265222399515 Search in Google Scholar
12. Xu H, Niu Y, Wang T, Liu S, Xu H, et al. Novel FGFR1 and KISS1R mutations in Chinese Kallmann syndrome males with cleft lip/palate. BioMed Res Int 2015;2015:649698.26199944 Search in Google Scholar
14. Marcos S, Sarfati J, Leroy C, Fouveaut C, Parent P, et al. The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients. J Clin Endocrinol Metab 2014;99:E2138–43.10.1210/jc.2014-211025077900 Search in Google Scholar
16. Al ST, Cottrell DA, Hughes CV. Dental findings associated with the malformations of CHARGE. Pediatr Dent 2002;24:43–6.11874058 Search in Google Scholar
17. Matsuo T, Okamoto S, Izumi Y, Hosokawa A, Takegawa T, et al. A novel mutation of the KAL1 gene in monozygotic twins with Kallmann syndrome. Eur J Endocrinol 2000;143:783–7.10.1530/eje.0.143078311124862 Search in Google Scholar
18. Nagata K, Yamamoto T, Chikumi H, Ikeda T, Yamamoto H, et al. A novel interstitial deletion of KAL1 in a Japanese family with Kallmann syndrome. J Hum Genet 2000;45:237–40.10.1007/s100380070033 Search in Google Scholar
19. Dode C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2006;2:e175.1705439910.1371/journal.pgen.0020175 Search in Google Scholar
20. Monnier C, Dode C, Fabre L, Teixeira L, Labesse G, et al. PROKR2 missense mutations associated with Kallmann syndrome impair receptor signalling activity. Hum Mol Genet 2009;18:75–81.1882696310.1093/hmg/ddn318 Search in Google Scholar
21. Sarfati J, Dode C, Young J. Kallmann syndrome caused by mutations in the PROK2 and PROKR2 genes: pathophysiology and genotype-phenotype correlations. Front Horm Res 2010;39:121–32.10.1159/00031269820389090 Search in Google Scholar
22. Kim HG, Ahn JW, Kurth I, Ullmann R, Kim HT, et al. WDR11, a WD protein that interacts with transcription factor EMX1, is mutated in idiopathic hypogonadotropic hypogonadism and Kallmann syndrome. Am J Hum Genet 2010;87:465–79.2088796410.1016/j.ajhg.2010.08.018 Search in Google Scholar
23. Ribeiro RS, Vieira TC, Abucham J. Reversible Kallmann syndrome: report of the first case with a KAL1 mutation and literature review. Eur J Endocrinol 2007;156:285–90.10.1530/eje.1.0234217322486 Search in Google Scholar
24. Sarfati J, Fouveaut C, Leroy C, Jeanpierre M, Hardelin JP, et al. Greater prevalence of PROKR2 mutations in Kallmann syndrome patients from the Maghreb than in European patients. Eur J Endocrinol 2013;169:805–9.10.1530/EJE-13-041924031091 Search in Google Scholar
25. Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, et al. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci USA 2010;107:15140–4.10.1073/pnas.1009622107 Search in Google Scholar
The online version of this article offers supplementary material (https://doi.org/10.1515/jpem-2017-0035).
©2017 Walter de Gruyter GmbH, Berlin/Boston